PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026EJNMMI Radiopharmacy and Chemistry0 citationsOpen Access

Synthesis and preclinical development of a novel 68Ga/89Zr-Labelled ανβ6-integrin targeting trimer

CDClemens DecristoforoGGGiacomo GariglioFPFlavia Patino

Key Points

  • To develop and optimize a novel 68Ga/89Zr-labelled tracer targeting the αvβ6 integrin for improved imaging applications.
  • Synthesis of FSC(PEG4-αvβ6)₃ targeting integrin αvβ6
  • Application of multifaceted chelator Fusarinine C
  • Use of Gallium-68 and Zirconium-89 for radiolabeling
  • The novel tracer demonstrates effective targeting of αvβ6 integrin
  • Expanded radionuclide application from Gallium-68 to Zirconium-89
  • Promising preclinical outcomes for clinical translation and imaging advancements

Abstract

FSC(PEG4-αvβ6)₃ represents the first-generation tracer targeting the αvβ6 integrin based on the multifunctional chelator Fusarinine C, thereby expanding the repertoire of radionuclides applicable from Gallium-68 to Zirconium-89. Following further optimization, this novel class of compounds holds significant promise for enabling clinical translation and advancing the development of next-generation αvβ6-directed imaging agents.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Decristoforo et al. (2026) studied this question.

synapsesocial.com/papers/698827670fc35cd7a884627chttps://doi.org/10.1186/s41181-025-00423-x
Ask AI
Helpful
Bookmark
Share
View Full Paper